Holen Sie sich die Stockscreener-App
6.99
7.70%
0.50
Vorhandelsmarkt:
7.08
0.09
+1.29%
Schlusskurs vom Vortag:
$6.49
Offen:
$6.54
24-Stunden-Volumen:
516.65K
Relative Volume:
0.83
Marktkapitalisierung:
$663.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.36M
KGV:
-1.5908
EPS:
-4.394
Netto-Cashflow:
$-15.05M
1W Leistung:
-0.14%
1M Leistung:
+16.31%
6M Leistung:
+237.68%
1J Leistung:
+507.83%
1-Tages-Spanne:
$6.43
$7.0599
1-Wochen-Bereich:
$6.30
$7.10
52-Wochen-Spanne:
$0.97
$7.19
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.99 | 615.78M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Wedbush | Outperform |
| 2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Yahoo Finance Singapore
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
ZURA Should I Buy - Intellectia AI
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com Australia
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Leaders behind four approved immunology drugs join Zura Bio board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - Yahoo Finance
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks
Zura Bio Ltd Provides Updated Corporate Presentation - TradingView
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wedbush initiates coverage on Zura Bio stock with Outperform rating By Investing.com - Investing.com India
Wedbush initiates coverage on Zura Bio stock with Outperform rating - Investing.com
Wedbush Initiates Zura Bio at Outperform With $15 Price Target - marketscreener.com
Investment Report: Will Zura Bio Limited benefit from rising consumer demand2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Aug Update: Will Zura Bio Limited benefit from rising consumer demandJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - ChartMill
Watch Zura Bio's Guggenheim biotech summit fireside chat live online - Stock Titan
Aug Sectors: What makes Zura Bio Limited stock attractive todayTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market volume spike for 94E.F Zura Bio (XETRA) 28 Jan 2026: watch EUR 5.20 level - Meyka
Zura Bio (NASDAQ:ZURA) Trading Up 0.3%What's Next? - MarketBeat
Zura Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Parvinder Thiara - Longbridge
Zura Bio Ltd Announces CEO Transition and Board Appointment - TradingView
Does Zura Bio Limited have pricing power2025 Technical Overview & Weekly Consistent Profit Watchlists - mfd.ru
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
Can Zura Bio Limited stock double in the next yearJuly 2025 Fed Impact & High Return Trade Opportunity Guides - baoquankhu1.vn
Zura Bio appoints Sandeep Kulkarni as new CEO By Investing.com - Investing.com South Africa
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):